GSK (NYSE:GSK - Get Free Report) announced its quarterly earnings results on Wednesday. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15, Zacks reports. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.
GSK Price Performance
GSK stock traded down $0.35 during trading hours on Friday, hitting $36.03. 5,356,346 shares of the stock traded hands, compared to its average volume of 4,879,423. The stock has a 50-day simple moving average of $34.25 and a 200 day simple moving average of $37.56. The company has a market cap of $74.68 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. GSK has a one year low of $31.72 and a one year high of $45.92. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12.
GSK Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.36%. GSK's dividend payout ratio is 93.08%.
Analysts Set New Price Targets
GSK has been the subject of several recent research reports. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday. Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.25.
Check Out Our Latest Stock Analysis on GSK
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
